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MicrobicideHuman papillomaviruses (HPV) are common sexually transmitted pathogens that predispose women to
cervical and other anogenital cancers. HPV vaccines can prevent infection by some but not other sexually
transmitted HPVs but are too costly for use in much of the world at greatest risk to HPV-associated cancers.
Microbicides provide an inexpensive alternative to vaccines. In a high throughput screen, drugs that inhibit
the cellular protein complex known as gamma secretase were identiﬁed as potential HPV microbicides.
gamma Secretase inhibitors (GSIs) inhibited the infectivity of HPV pseudoviruses both in human
keratinocytes and in mouse cells, with IC50 values in the picomolar to the nanomolar range. Using a mouse
model, we observed that a GSI could inhibit HPV infection to the same degree as its effectiveness in inhibiting
gamma secretase activity in vivo.We conclude that gamma secretase activity is required for HPV infection and
that GSIs are effective microbicides against anogenital HPVs.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Papillomaviruses (PVs) are a diverse group of small, nonenveloped
double stranded DNA tumor viruses that infect the skin and mucosal
tissues and cause benign lesions called papillomas or warts in a wide
variety of animals, such as rabbit, bovine, and human. An etiological
association of human papillomarviruses (HPVs) with cervical cancer
was ﬁrst identiﬁed in the laboratory of Dr. Harald zur Hausen (Durst et
al., 1983). A subset of about a dozen sexually-transmitted HPV
genotypes, so-called ‘high risk’ HPVs, collectively cause nearly all cases
of cervical cancer. A single genotype, HPV16, causes approximately half
of all cervical cancers, aswell as a substantial fraction of other anogenital
cancers and head-and-neck cancers (zur Hausen, 2009; Smith et al.,
2007). The different, relatively non-carcinogenic pair of HPV genotypes,
HPV6 and HPV11, causes genital warts, known as condylomata
acuminata (Lacey et al., 2006). Although approximately 75% of sexually
active adults become infected with one or more anogenital HPV types
(Koutsky, 1997), most HPV infections are transient and asymptomatic,
and about 90% of HPV infected women become HPV DNA negative
within twoyears (Hoet al., 1998).However, aminority of high riskHPV-
infected individuals develop persistent HPV infection that can lead to
the development of cervical cancer, other anogenital cancers, and a
subset of head-and-neck cancers.
Two highly effective prophylactic HPV vaccines, Cervarix and
Gardasil, are currently available. These vaccines prevent infection by
HPV genotypes 16 and 18 and, in the case of Gardasil, also by HPVs 6and 11 (Garland et al., 2007; Paavonen et al., 2007). One drawback to
these vaccines is that they do not protect against the full range of
cancer-causing HPV serotypes. The vaccines are also relatively
expensive, which limits their availability in developing countries
wherein there is the highest risk of developing cervical cancer because
of inadequate screening using the Pap smear. Thus, the development
of inexpensive and broad-spectrum topical microbicides active
against sexually-transmitted HPVs could provide additional protec-
tion against HPV serotypes not covered by the vaccines and serve as
useful, inexpensive adjuncts to vaccination programs.
Results
gamma Secretase inhibitors block papillomavirus infection in a
dose-dependent manner
In a directed, HPV16 reporter pseudovirus-based screen of various
commercially-available drugs, we discovered that inhibitors of the
cellular protein complex known as gamma secretase efﬁciently blocked
the infectivity of the pseudovirions at non-cytotoxic doses. In secondary
screens, we conﬁrmed the ability of two gamma secretase inhibitors,
numbers IX and X, to inhibit HPV infection in immortalized human
keratinocytes (HaCat cells), with IC50 values in the picomloar to
nanomolar range (Figs. 1A and B). Similar results were observed when
HPV16-GFP pseudovirions that matured under neutral buffered condi-
tionswere testedagainst gammasecretase inhibitorX (datanot shown).
To test whether the inhibitory effects of GSI-IX and GSI-X are HPV
genotype or human cell type-speciﬁc, we repeated the luciferase and
cell viability assays in mouse keratinocyte C127 cells with HPV16:LucF
pseudovirus (Figs. 1C and D), and in HaCat cells with HPV11:LucF or
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of the cell or virus types evaluated, the IC50 values of gamma secretase
inhibitors IX and X in blocking HPV infection were consistently in the
picomolar to the nanomolar range, respectively. We also conducted a
focal transformation assay using mouse C127 cells and native bovine
papillomavirus type 1 (BPV1) virions isolated from bovine warts to
conﬁrm the capacity of gamma secretase inhibitors to block infection by
naturally sourced papillomavirus (Fig. 4). These data indicate that GSI-
IX and GSI-X function as potential microbicides for a wide range of
different papillomavirus species.
gamma Secretase inhibitors block the infectivity of cell-bound virions
Previous studies have shown that papillomavirus infection of
cultured cells is an unusually protracted process compared to the
infection kinetics of many other viral families (Buck et al., 2006),
reviewed in Day and Schiller (2009). Thus, drugs that target the
papillomavirus infectious entry process may have a window of many
hours during which to act. To assess at what stage of infection gamma
secretase inhibitors acted to inhibit papillomavirus infection, we
performed time of addition studies. We observed that, even at
12 hours post pseudovirus exposure, GSI-X treatment resulted in nearly
complete blocking of the infectivity of the pseudovirus inoculum
(Fig. 5). However, infection was inefﬁciently blocked when drug was
added at later time points. These results suggest that gamma secretase
activity is required for a relatively late step during the papillomavirus
infectious entry process.
gamma Secretase inhibitors reduce HPV infection signiﬁcantly in mouse
female reproductive tract
The ultimate goal of our studies is to identify potential HPV
microbicides as an economical adjunct to HPV vaccines for preventing
sexual transmission of HPVs. To this end, we tested whether topical
treatment of GSI-IX and GSI-X inhibit the infectivity of HPV
pseudoviruses in the female murine reproductive tract, using a
modiﬁed version of the in vivo infection assay recently developed by
the laboratory of Dr. John Schiller (Roberts et al., 2007). This mouse
model provides a novel mean to recapitulate the initial phases of
papillomavirus infection in cervicovaginal epithelia. Speciﬁcally it
allows one to monitor binding, entry, and delivery of encapsidated
DNA to the nucleus, which represent earliest steps in the natural
infectious life cycle. The efﬁciency of this process is greatly increased
by mechanical or chemical disruption of the cervicovaginal epitheli-
um. In the case of our studies, we used pretreatment with nanoxynol-
9, a detergent and spermicidal agent. HPV16:LucF was instilled into
the female genital tract in the presence or absence of gamma secretase
inhibitors. Tissue lysates of reproductive tracts were harvested for
luciferase assays after an infection period of 2 days. We observed an
approximately 50% reduction in luciferase activity in mice that were
administered GSI-X prior to HPV16 pseudovirion inoculation (Fig. 6).
Given the modest reduction in HPV pseudovirus infection observed in
vivo upon topical treatment with GSI-IX (data not shown) and GSI-X,
we pursued additional studies in which we examined the effective-
ness of GSI-IX as a microbicide when delivered systemically (due to
toxicity, systemic delivery of GSI-X is not possible). Using a
ﬂuorogenic substrate, we found that gamma secretase activity was
reduced by 50% in the presence of sera frommice treated systemically
with GSI-IX (data not shown), consistent with prior studies (Comery
et al., 2005). There was likewise a 50% reduction in HPV16
pseudovirus infectivity in mice systemically treated with GSI-IXFig. 1. Cell cytotoxicity (cell viability assays) and infectivity of HPV16 pseudovirus (luciferas
cells, were treated with serial dilutions of (A) GSI-IX or (B) GSI-X 4 hours prior to HPV16 pse
(D) GSI-X 4 hours prior to HPV16 pseudovirus exposure. Bioluminescent signals of cells wi(Fig. 7). The results support the hypothesis that inhibition of gamma
secretase inhibits HPV infection.
Discussion
Our data indicate that gamma secretase inhibitors IX and X inhibit
the infectivity of papillomaviruses. In tissue culture, their IC50 values
are amongst the best of any HPV microbicide identiﬁed to date, and
their inhibitory effects are active against a range of papillomavirus
species. GSI-IX inhibited HPV pseudovirus infection of the female
reproductive tract in live mice to the same extent as its effectiveness
in inhibiting gamma secretase activity in vivo. These studies indicate
that gamma secretase activity is essential for HPV infection and the
inhibitors of gamma secretase may be effective microbicides for HPV.
Our ﬁndings are corroborated by a coincident study performed in the
laboratory of Richard Roden that is in press.
Since these gamma secretase inhibitors can inhibit infectivity for
up to 12 hours after pseudovirion exposure in vitro, it seems likely
that the gamma secretase inhibitors inhibit a relatively late step in the
infectious entry process. gamma Secretase catalyzes the proteolytic
cleavage of the transmembrane domains of a variety of protein
substrates. Thus, one hypothesis would be that gamma secretase's
proteolytic function is required for cleavage of a cellular protein
involved in infectious entry. Another possibility would be that gamma
secretase must cleave one of the viral capsid proteins after their
insertion into a cellular membrane. To examine this latter hypothesis,
we performed a series of experiments in which pseudovirions were
applied to cells for varying amounts of time in the presence or absence
of gamma secretase inhibitors and hypothetical cleavage of the capsid
proteins wasmonitored byWestern blotting. In these experiments, no
gamma secretase-speciﬁc cleavage of L1 or L2 was observed (unpub-
lished result). However, it remains conceivable that too small a fraction
of either protein is cleaved by gamma secretase to be detected by
Western blotting. Further study is needed to deﬁne the relevant target
(s) of gamma secretase that are critical for efﬁcient HPV infection.
Although gamma secretase inhibitors are exceptionally potent for
inhibiting papillomavirus infectivity in vitro, it appears that their use
as topically-applied microbicides in vivo may be limited by their
bioavailability in the genital tract. The result highlights the impor-
tance of validating candidate microbicides in live animal models, such
as the modiﬁed mouse challenge model reported here.
Materials and methods
Cell cultures
293FT cells (human kidney 293 cells expressing SV40 large T
antigen) (Invitrogen) and HeLa cells were maintained in DMEM
medium (high glucose) (Invitrogen) containing 10% fetal bovine
serum (Harlan) supplemented with 0.1 mM MEM non-essential
amino acids (Invitrogen), 1 mM sodium pyruvate (Invitrogen),
2 mM L-glutamine (Invitrogen), and 500 μg/mL Geneticin. HaCat
cells (spontaneously immortalized human keratinocytes) were
cultured in F12/DMEM (1:1) medium (Invitrogen) containing 10%
fetal bovine serum. C127 mouse keratinocytes were cultured in
DMEM medium containing 10% fetal bovine serum.
gamma Secretase inhibitors and substrate
gamma Secretase inhibitors, numbers IX (GSI-IX, N-[N-(3,5-
diﬂuorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester, DAPT)
(Calbiochem, Cat. # 565784 and # 565770) and numbers X (GSI-X,e assays) in cells treated with gamma secretase inhibitors. Human keratinocytes, HaCat
udovirus exposure. Mouse C127 cells were treated with serial dilutions of (C) GSI-IX or
th mock treatment (HPV16 pseudovirus only) were set as 100%, respectively. N=6.
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Fig. 2. Cell cytotoxicity (cell viability assays) and infectivity of HPV11 and HPV31
pseudovirus (luciferase assays) in HaCat cells treated with gamma secretase inhibitor
IX. HaCat cells were treated with serial dilutions of GSI-IX 4 hours prior to (A) HPV11
pseudovirus or (B) HPV31 pseudovirus exposure. N=6.
Fig. 3. Cell cytotoxicity (cell viability assays) and infectivity of HPV11 and HPV31
pseudovirus (luciferase assays) in HaCat cells treated with gamma secretase inhibitor X.
HaCat cells were treated with serial dilutions of GSI-X 4 hours prior to (A) HPV11
pseudovirus or (B) HPV31 pseudovirus exposure. N=6.
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methylbutylcarbamoyl]-2R-hydroxy-5-phenylpentyl}carbamic acid
tert-butyl ester) (Calbiochem, Cat. # 565771), were dissolved in
100% DMSO. gamma Secretase substrate, ﬂuorogenic (NIMA-
GGVVIATVK(DNP)-DRDRDR-NH2) (Calbiochem, Cat.# 565764).Generation of HPV16:LucF pseudoviruses (PVs) and directed drug screens
HPV virus-like particles (VLPs) carrying encapsidated reporter
plasmids are referred in the papillomavirus ﬁeld as HPV pseudo-
viruses. Reporter pseudovirions were produced using previously-
described methods (Buck et al., 2004; Buck and Thompson, 2007).
Brieﬂy, two plasmids were cotransfected into 293FT. One plasmid is
p16SheLL, a 10.8 kilo base pair (kbp) plasmid (too large to be
packaged in HPV VLPs) that expresses the HPV16 major capsid
protein, L1, and minor capsid protein, L2. The second plasmid is pLucF
that encodes both ﬁreﬂy luciferase (Luc) and green ﬂuorescent
protein (GFP) and is encapsidated efﬁciently. Pseudovirions were
harvested by detergent lysis of the cells 48 hours after transfection.
Particles were allowed to mature overnight (Buck et al., 2005) and
were puriﬁed by ultracentrifugation through OptiPrep gradients. The
titers of HPV16:LucF pseudoviruses were determined by ﬂow
cytometric analysis of 293FT cells treated with various dilutions of
puriﬁed pseudovirion stock.For initial drug screening experiments, anHPV16-basedpseudovirus
encoding GFP was used to infect HeLa cells pre-plated a day in advance
at 7500 cells/well in 96-well plates. A variety of drugs were selected
from the EMDBiosciences or Sigma-Aldrich catalogs. Drug selectionwas
essentially based on guesswork informed by reviews of relevant
literature. Each candidate entry inhibitor drug was subjected to serial
dilution and applied to the cell cultures for 30 minutes prior to addition
of 6×104 GFP transducing units of HPV16 pseudovirus stock. Inhibition
of pseudovirus infectivity wasmonitored by ﬂow cytometric analysis of
the cell cultures 48 hours after addition of the pseudovirions.
Dose-dependent luciferase assays and cell viability assays
A total of 1×104 HaCat or C127 cells per well in 96-well plates
were pretreated with serial dilutions of gamma secretase inhibitor IX
or X (Calbiochem) (from 0 to 10 μM) 4 hours prior to addition of
1×105 GFP transducing units of HPV16:LucF pseudovirus (10 M.O.I.).
Seventy-two hours after pseudovirus treatment, cells were lysed, and
the infectivity was measured by quantitative luciferase assays
(Promega, Luciferase Assay System Cat. #1501 and #1531). Parallel
cell viability assays (Promega, Luminescent Cell Viability Assay Cat.
#G7571) were performed to monitor the cytotoxicity of the gamma
secretase inhibitors IX and X. Alternatively, experiments above were
repeated by using HPV11:LucF and HPV31:LucF instead of HPV16:
LucF in HaCat cells.
Fig. 4. Infectivity of native bovine papillomavirus type 1 (BPV1) in mouse C127 cells
treated with gamma secretase inhibitors. Mouse C127 cells were treated with serial
dilutions of (A) gamma secretase inhibitor IX or (B) gamma secretase inhibitor X 4 hours
prior to native bovine papillomavirus type 1 exposure. Twenty-four hours after BPV1
exposure, the cells were washed to remove unbound BPV1 and gamma secretase
inhibitors. About 2 to 3 weeks later, infectivity was determined by the efﬁciency of focal
transformations. Focus of mock treatment (BPV1 only) was set as 100%.
Fig. 6. Infectivity of HPV16 pseudovirus in mouse reproductive tracts treated with
gamma secretase inhibitor X topically. DMSO or GSI-10 was delivered with or without
HPV16 pseudoviruses in mouse reproductive tracts. The time point for exposure to
HPV16 pseudoviruses was set as 0 hour. Forty-eight hours later, mouse female
reproductive tracts were harvested, protein lysates were made, and luciferase assays
were carried out to quantify the infectivity. Tissue lysates from mice receiving DMSO
with or without HPV16 pseudovirus was used as positive and negative controls,
respectively. The infectivity level (luciferase assay) of positive control was set as 100%.
N=7, */**Pb0.05 (Wilcoxon rank sum test, 2 sided).
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The ability of gamma secretase inhibitors to block the infectivity of
authentic papillomavirus virions was examined using a previously-Fig. 5. Infectivity of HPV16 pseudovirus in HaCat cells treated with gamma secretase
inhibitor X at different time points (time course luciferase assays). HaCat cells were
treated with 1 nMGSI-X at the time relative to HPV16 pseudovirus infection, which was
set as 0 hour. For the last three conditions, cells were washed to remove GSI-X at
indicated time points. Forty-eight hours post infection, infectivity was determined by
performing luciferase assays. The x axis represents the time at which HaCat cells were
treated with GSI-X. Each condition was normalized with individual internal controls
(same condition without DMSO or GSI-X), and the bioluminescent signal of cells with
mock treatment (DMSO only) was set as 100%. N=12.described assay for cellular transformation by bovine papillomavirus
type 1 (Dvoretzky et al., 1980). Brieﬂy, 1×105 C127 cells (immortalized
mouse keratinocytes) were pre-plated in 60 mm culture dishes
overnight then treated with serial dilutions of gamma secretase
inhibitors IX or X (from 0 to 1 μM) for 4 hours. After drug treatment,
the cell monolayer was exposed to native BPV1 virions isolated from
bovine skin warts. Twenty-four hours after BPV1 exposure, the cells
werewashed to removeunboundBPV1andgammasecretase inhibitors.
Focal transformations were detected by staining the cell cultures with
1% methylene blue 2 to 3 weeks later.
Time course luciferase assays
We set the time at which HaCat cells were exposed to HPV16
pseudovirus as the 0 hour. We treated or mock-treated 1×104HaCat
cells with 1×105 HPV16:LucF (10 M.O.I.) and added 1 nM gamma
secretase inhibitor X or 2% DMSO (vehicles) at different time pointsFig. 7. Infectivity of HPV16 pseudovirus inmouse reproductive tracts treatedwith gamma
secretase inhibitor IX systemically. The time point for exposure to HPV16 pseudoviruses
was set as 0 hour. At −4 and 0 hours mice were fed with DMSO or GSI-IX. Forty-eight
hours later, mouse female reproductive tracts were harvested, protein lysates weremade,
and luciferase assays were carried out to quantify the infectivity. Tissue lysates frommice
receiving DMSO with or without HPV16 pseudovirus was used as positive and negative
controls, respectively. The infectivity level (luciferase assay) of the positive control was set
as 100%. N=6, */**P=0.07 (Wilcoxon rank sum test, 2 sided).
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or GSI-X were performed to serve as controls. Forty-eight hours after
infection, cells were lysed, and luciferase assays were performed to
measure the efﬁciency of infection.
Mouse model for quantifying the in vivo efﬁciency of HPV infection
HPV16:LucF pseudoviruses were used to establish a quantitative
mouse infection model for HPV in the female reproductive tract. The
method is a modiﬁed version of a previously published model (Roberts
et al., 2007). Indicated numbers of HPV16 pseudovirus were delivered
intravaginally in 4% carboxyl methyl cellulose (Sigma Cat. #C4888)
using six or seven 6- to 8-week-old virgin female mice per condition.
The mice were prepared by subcutaneous injection with 3 mg
medroxyprogesterone acetate (Sicor, Depo-Provera) in 1× PBS 4 days
prior to pseudovirus challenge to induce diestrus. Six hours prior to
pseudovirus instillation, the mice were pre-treated vaginally with
Conceptrol (Caldwell Consumer Health), an over-the-counter spermi-
cide product containing 4% nonoxynol-9. Administration of nonoxynol-
9 has previously been shown to potentiate HPV pseudovirus infection
due to chemical injury of the vaginal/cervical epithelium (Roberts et al.,
2007). Forty-eight hours after delivery of the pseudovirions, mouse
female reproductive tracts were harvested, protein lysates were made,
and luciferase assays were carried out to quantify the efﬁciency of
infection in a dose-dependent manner.
Assessment of GSI microbicidal activity in the mouse challenge model
Topical treatment of gamma secretase inhibitors
The time point for exposure to 3×106 HPV16:LucF pseudoviruseswas
set as 0 hour. To ensure that gamma secretase inhibitor was presented
during HPV16 pseudovirus infection, mice were treated topically with
2 μM or 20 μM gamma secretase inhibitor X at −2/zero/+4/+6/
+8 hours. Forty-eight hours after HPV16:LucF pseudovirus exposure,
infectivity was determined by quantitative luciferase assays as described
as above.
Systemic treatment of gamma secretase inhibitors
At −4 and 0 hours we fed mice with 2% DMSO or 2.5 mg gamma
secretase inhibitor IX, and 3×106 HPV16:LucF pseudoviruses were
delivered to the mouse reproductive tract at time 0. Four hours post
delivery of the pseudovirus, female reproductive tracts were
harvested, tissue lysates were made, and gamma secretase activity
was measured as described previously. Forty-eight hours after
pseudovirus treatment, another set of mouse female reproductivetracts was lysed and luciferase assays were carried out as described as
above.
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